source
- Curium to acquire Lantheus in deal valued up to $8 billionCurium announced it will purchase all outstanding shares of Lantheus for $102.50 cash per share, with potential additional $12 per share via contingent value rights linked to sales milestones in pr…
- Curium to acquire Lantheus in $8 billion deal, offering $102.5 per share with upside potentialCurium announced it will purchase radiopharmaceutical company Lantheus in a transaction valued at about $8 billion. The agreement sets the purchase price at $102.5 for each Lantheus share, and inc…